Flaxseed Compound May Help Prevent Malignant Mesothelioma and Asbestosis

prevent malignant mesothelioma with flaxseed compound?

There is new evidence that a compound found in flaxseeds may help prevent malignant mesothelioma and other asbestos-related diseases. The compound is an anti-inflammatory which appears to calm down the overactive immune system after asbestos exposure in mice. Inflammation has long been considered a key factor in the development of mesothelioma. Scientists are hopeful that preventing it may also prevent malignant mesothelioma. Inflammatory Response to Asbestos Exposure Asbestos is a group of naturally-occuring minerals that cause cancer in people and animals. When a person accidentally breathes in or swallows asbestos fibers, they trigger an inflammatory response that can last for years. White blood cells flock to the area and damaging free radicals are produced. Over time, some cells may become … Continue reading Flaxseed Compound May Help Prevent Malignant Mesothelioma and Asbestosis »

Mesothelioma Tumor Progression Can be Tracked With Blood Test

mesothelioma tumor progression

Italian researchers say it’s possible to monitor mesothelioma tumor progression with a simple blood test. They make their case in a Letter to the Editor in the latest edition of the Journal of Thoracic Oncology. The researchers say blood serum levels of the protein mesothelin correlate closely with tumor volume in malignant pleural mesothelioma patients. They are recommending that the blood test be used alongside CT to track mesothelioma tumor progression. The Importance of Monitoring Mesothelioma Tumor Progression Pleural mesothelioma is a rare cancer with a grim prognosis. Mesothelioma tumors tend to grow and spread quickly. Doctors have to carefully monitor mesothelioma tumor progression to tell if a treatment is working. Most mesothelioma patients have chemotherapy with Alimta (pemetrexed) and … Continue reading Mesothelioma Tumor Progression Can be Tracked With Blood Test »

Many Elderly Mesothelioma Patients Get No Treatment

elderly mesothelioma patients

The majority of elderly mesothelioma patients are observed rather than treated and this can have a negative impact on their survival. That is the finding of a new study published in the Annals of Surgical Oncology. The study included more than 4,500 mesothelioma patients. Less than a quarter of these patients received any treatment for their mesothelioma. As a result, most of these patients lived less than six months. Treatment Options for Elderly Mesothelioma Patients Exposure to asbestos causes pleural mesothelioma. It can take decades after exposure for mesothelioma symptoms to occur. The median age for a malignant pleural mesothelioma diagnosis is 72. The older a patient is at diagnosis, the more likely they are to have other health problems. … Continue reading Many Elderly Mesothelioma Patients Get No Treatment »

Risk for Mesothelioma Does Not Decline After Asbestos Exposure Stops

Asbestos worker faces risk for mesothelioma

A new report contains some disappointing news for former asbestos workers: The risk for mesothelioma does not go down when asbestos exposure stops. A team of US and Italian researchers reached that conclusion after combing the medical literature for studies on the risk for mesothelioma. Although the risk for several other cancers declines when the person is no longer in contact with the carcinogen, the study shows this does not apply to asbestos cancer. Asbestos Increases Mesothelioma Risk Asbestos is the primary cause of mesothelioma. It is a naturally-occurring mineral that is resistant to corrosion, does not burn, and makes an excellent insulator. Malignant mesothelioma was virtually unheard of until people started mining and using asbestos in industry. Since then, … Continue reading Risk for Mesothelioma Does Not Decline After Asbestos Exposure Stops »

Lower-Volume Centers Less Likely to Follow Mesothelioma Treatment Guidelines

mesothelioma treatment guidelines

Mesothelioma patients need to beware of low-volume centers that are less likely to follow mesothelioma treatment guidelines. That is the message from a new study based on data from the National Cancer Institute. The study was run by doctors at Cedars-Sinai Medical Center in Los Angeles. It shows that treatment centers that do not see a lot of mesothelioma cases are less likely to follow the life-saving mesothelioma treatment guidelines. As a result, patients treated in these lower-volume facilities tend to have shorter mesothelioma survival. What are the Mesothelioma Treatment Guidelines? Malignant pleural mesothelioma is a cancer that occurs on the membrane that surrounds the lungs. It is extremely rare and difficult to treat. Many hospitals and doctors never see … Continue reading Lower-Volume Centers Less Likely to Follow Mesothelioma Treatment Guidelines »

Metastatic Mesothelioma: Does Chemotherapy Work?

metastatic mesothelioma

New research out of Pennsylvania suggested that not all people with metastatic mesothelioma will live longer with chemotherapy. Although chemotherapy is the primary treatment for malignant pleural mesothelioma, some types of metastatic mesothelioma appear to be less responsive than others. In some cases, the researchers say best supportive care may be a better option for preserving a patient’s quality of life. Three Mesothelioma Subtypes There are three histological subtypes of malignant pleural mesothelioma. The categories are based on how the cells look under a microscope. Cell type appears to influence how aggressive they are as metastatic mesothelioma. Cell type also factors into mesothelioma prognosis. Epithelioid mesothelioma is the most common cell type. Epithelioid cells tend to lack uniformity and may … Continue reading Metastatic Mesothelioma: Does Chemotherapy Work? »

Study Highlights How Genes Impact Mesothelioma Survival

Genes impact mesothelioma survival

A new National Cancer Institute study shines a light on some of the ways genes impact mesothelioma survival. It could have important implications for mesothelioma treatment. The study was led by prominent mesothelioma researcher Raffit Hassan, MD. It focused on genetic mutations that may make certain mesothelioma patients more sensitive to chemotherapy. Genes, Genotype, and Mesothelioma Treatment A mesothelioma patient’s unique collection of genes, including genetic mutations, is known as their genotype. Genes impact mesothelioma survival in a variety of ways. Tumor suppressor genes are supposed to help keep tumors from forming. People with mutations on these genes may be more likely to get malignant mesothelioma. Other genes influence the cancer’s ability to “hide” from detection by the immune system. … Continue reading Study Highlights How Genes Impact Mesothelioma Survival »

Needle Procedure Could Prevent Unneeded Surgery for Malignant Mesothelioma

surgery for malignant mesothelioma

A minimally invasive method for cancer staging could prevent unnecessary surgery for malignant mesothelioma. The method involves putting a needle into the chest behind the breast bone. This area is called the mediastinum. The mediastinum contains critical lymph nodes. The presence or absence of cancer cells in these nodes can help determine whether a patient needs surgery for malignant mesothelioma. Now, a group of Canadian doctors say an ultrasound-guided needle biopsy procedure can provide as much information as more invasive options with less risk and pain. Staging Helps Direct Surgery for Malignant Mesothelioma Most mesothelioma patients receive chemotherapy. If the patient is healthy enough and the cancer has not spread, the patient may also have surgery for malignant mesothelioma. Some … Continue reading Needle Procedure Could Prevent Unneeded Surgery for Malignant Mesothelioma »

Combination Mesothelioma Therapy Begins Pivotal Trial

mesothelioma treatment combination

A combination mesothelioma therapy that showed promise in early trials is finally being studied on a larger scale. The power-packed chemo-immuno-gene therapy known as TR002 has the potential to change the outlook for thousands of malignant mesothelioma patients. A small trial of the combination mesothelioma therapy in 2016 produced “significantly higher” mesothelioma survival rates than most patients are told to expect. Drug company Trizell announced last month that the combination will now be tested on 300 patients at sites in the US, Europe, Australia and Russia. Combination Mesothelioma Therapy Starts with Gene Therapy TR002 is an investigational gene therapy for mesothelioma patients who have failed first-line chemotherapy. This combination mesothelioma therapy is based on the human interferon-alpha 2b gene. The … Continue reading Combination Mesothelioma Therapy Begins Pivotal Trial »

Get your free copy of
“Surviving Mesothelioma” Today!